Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (INBX) Stock Overview
Explore Inhibrx Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
212.4M
P/E Ratio
0.13
EPS (TTM)
$119.02
ROE
11.01%
INBX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Inhibrx Biosciences, Inc. (INBX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $25.12.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.13 and a market capitalization of 212.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Mark Paul Lappe
156
11025 North Torrey Pines Road, La Jolla, CA
2024